Latest Breaking News On - Paul estrem - Page 3 : comparemela.com

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery Font : A-A+ WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.” Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death.

United statesPaul estremAlisa holstJames harveyKimr tsuchimotoPriscilla harlanAndrew mazarExchange commissionTrademark officeMonopar therapeutics incNorthstar medical radioisotopesChief scientific officerStar medical radioisotopesDrug administrationPrivate securities litigation reform actInvestor relations